Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease

US11096910B2 · kind B2 · utility

Assignees

• Max Delbrück-Centrum Für Molekulare Medizin · DE
• The Board of Regents of the University of Texas System · US
• OMEICOS Therapeutics GmbH · DE

Inventors

• Robert Fischer · Berlin, DE
• Anne Konkel · Berlin, DE
• Tim Wesser · Berlin, DE
• Philipp Westphal · Berlin, DE
• Wolf-Hagen Schunk · Berlin, DE
• Christina Westphal · Berlin, DE
• John R. Falck · University Park, US

Key dates

• Filing date: Jul 22, 2016
• Grant date: Aug 24, 2021
• Expiry date: Jul 22, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/5375
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of cardiovascular diseases.